BACKGROUND: Neurocognitive problems have been observed in a number of women previously treated with adjuvant chemotherapy for breast cancer. The present study aims to combine the results of neuropsychological and electrophysiological techniques collected in patients with breast cancer treated with cyclophosphamide/methotrexate/5-fluorouracil (CMF) at different time points. PATIENTS AND METHODS: Patients with breast cancer treated with adjuvant CMF chemotherapy (n = 63) were examined with neuropsychological tests 1 year after treatment and compared with healthy women (n = 60; T1 portion of the study). Based on neuropsychological test performance, patients were classified as cognitively impaired or unimpaired. Four years later, behavioral and neurophysiological measures (T2 portion of the study) were collected during an information-processing task in a subgroup of patients (n = 26). At T2, we compared the results of cognitively impaired patients (n = 8) with those of patients classified as cognitively unimpaired at T1 (n = 18). RESULTS: In the initial neuropsychological assessment, 33.3% of the patients were classified as cognitively impaired, compared with 10% of healthy women. At T2, impaired patients who received CMF showed longer P3 latencies, lower P3 amplitudes, longer reaction times, and made more errors in an information processing task compared with unimpaired patients who received CMF. CONCLUSION: The results indicate the persistence of neurocognitive problems < or = 5 years after completion of chemotherapy and consistency across different assessment techniques.
BACKGROUND: Neurocognitive problems have been observed in a number of women previously treated with adjuvant chemotherapy for breast cancer. The present study aims to combine the results of neuropsychological and electrophysiological techniques collected in patients with breast cancer treated with cyclophosphamide/methotrexate/5-fluorouracil (CMF) at different time points. PATIENTS AND METHODS: Patients with breast cancer treated with adjuvant CMF chemotherapy (n = 63) were examined with neuropsychological tests 1 year after treatment and compared with healthy women (n = 60; T1 portion of the study). Based on neuropsychological test performance, patients were classified as cognitively impaired or unimpaired. Four years later, behavioral and neurophysiological measures (T2 portion of the study) were collected during an information-processing task in a subgroup of patients (n = 26). At T2, we compared the results of cognitively impairedpatients (n = 8) with those of patients classified as cognitively unimpaired at T1 (n = 18). RESULTS: In the initial neuropsychological assessment, 33.3% of the patients were classified as cognitively impaired, compared with 10% of healthy women. At T2, impaired patients who received CMF showed longer P3 latencies, lower P3 amplitudes, longer reaction times, and made more errors in an information processing task compared with unimpaired patients who received CMF. CONCLUSION: The results indicate the persistence of neurocognitive problems < or = 5 years after completion of chemotherapy and consistency across different assessment techniques.
Authors: J A Lawrence; L Griffin; E P Balcueva; D L Groteluschen; T A Samuel; G J Lesser; M J Naughton; L D Case; E G Shaw; S R Rapp Journal: J Cancer Surviv Date: 2015-07-01 Impact factor: 4.442
Authors: Thomas R Groves; Ryan Farris; Julie E Anderson; Tyler C Alexander; Frederico Kiffer; Gwendolyn Carter; Jing Wang; Marjan Boerma; Antiño R Allen Journal: Behav Brain Res Date: 2016-09-04 Impact factor: 3.332
Authors: Sherifa A Hamed; Zahra I Selim; Amal M Elattar; Yasser M Elserogy; Eman A Ahmed; Hanan O Mohamed Journal: Clin Rheumatol Date: 2011-06-22 Impact factor: 2.980
Authors: Debra L Barton; Kelli Burger; Paul J Novotny; Tom R Fitch; Sadhna Kohli; Gamini Soori; Mary Beth Wilwerding; Jeff A Sloan; Lisa A Kottschade; Kendrith M Rowland; Shaker R Dakhil; Daniel A Nikcevich; Charles L Loprinzi Journal: Support Care Cancer Date: 2012-11-13 Impact factor: 3.603